Daughter wants ‘answers' on Hogan's death
Just two days after insisting that the wrestling legend's chronic lymphocytic leukaemia (CLL) diagnosis was 'weird,' the 37-year-old told her Instagram followers why she found this health update so 'shocking'.
She explained, 'I don't think anyone thinks there's foul play suspected, but the man had a very complicated medical history,' the New York Po st reports.
Hulk Hogan died last month aged 75 in Tampa, Florida.
Brooke claimed on Thursday to have seen 'MULTIPLE near-perfect blood panels' before 'all of a sudden everything [was] different'.
She claimed, 'Anyone would want answers'.
In a separate post to her Story, Brooke added, 'With all of the speculation and uncertainty of my dad's death, I want to personally offer to pay for an autopsy if that's what it takes to get it done. My dad's dignity and legacy deserves it'.
The former reality star initially 'freaked out' when she was told Hulk had been 'cremated without an autopsy' after his July 24 passing at age 71.
'He has not been cremated, and [his wife, Sky Daily], is doing the research,' Brooke clarified.
She first sparked conspiracy theories while calling into the Bubba the Love Sponge radio show Tuesday.
'Being through all the surgeries, you have to do a blood panel before any major surgery,' Brooke said.
'How did nobody catch a high white blood count? That's what bothers me the most.
'We don't have cancer that runs in our family,' she continued. 'It seems weird.'
Brooke was mostly 'puzzled' over Hulk's leukaemia diagnosis because 'he took the most care of his body' and 'was going to an anti-ageing specialist'.
Brooke, who asked to be removed from the athlete's will and skipped his funeral on Tuesday, noted, 'One doctor, I quote, said, 'His blood is like a 25-year-old''.
A report from the Pinellas County Forensic Science Centre, in Tampa, revealed Hulk's cancer battle last week, as well as his cause of death — acute myocardial infarction, commonly known as a heart attack.
In addition to Brooke and Daily, whom Hulk married in 2023, he is survived by his 35-year-old son, Nick Hogan, with ex-wife Linda Hogan.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
an hour ago
- News.com.au
Sharon Stone's rare red carpet appearance with all three of her sons
Sharon Stone is a proud boy mum. The actress, 67, was joined by her three sons, Roan, 25, Laird, 20, and Quinn, 19, for a rare red carpet appearance at Monday's premiere of her new film, Nobody 2, in Los Angeles. Stone wore a navy dress, glasses and a gold bangle bracelet as she posed for pictures with her boys, who all wore suits. Roan had on a pink suit, Laird opted for a grey suit, and Quinn went with a navy pinstripe suit. Along with her kids, Stone took photos with her co-stars Bob Odenkirk and Christopher Lloyd. The action thriller, also starring Connie Nielson, RZA, Colin Hanks, Michael Ironside and John Ortiz, is a sequel to 2021's Nobody, which follows a family man (Odenkirk) who returns to his former life as an assassin. Stone adopted her oldest son with her ex-husband, Phil Bronstein, in 2000. After the pair divorced in 2004, she adopted Laird in 2005 and Quinn in 2006. The Oscar nominee and Bronstein initially shared custody of Roan, but Roan ended up primarily living with his dad in San Francisco during the school year. Stone tried, and failed, to challenge the agreement. 'It broke my heart,' she said on the Table for Two with Bruce Bozzi podcast in 2023 about losing custody of Roan. 'I ended up in the Mayo Clinic with extra heartbeats in the upper and lower chambers of my heart.' Stone alleged that her role in the erotic thriller Basic Instinct affected her custody of Roan. 'When the judge asked my child – my tiny little boy, 'Do you know your mother makes sex movies?' This kind of abuse by the system, that it was considered what kind of parent I was because I made that movie,' she said. 'People are walking around with no clothes on at all on regular TV now and you saw maybe like a sixteenth of a second of possible nudity of me – and I lost custody of my child,' Stone added. Stone, who has been a single mum since her divorce, has maintained a close bond with her boys. In May, Stone shared a throwback photo of her sons swimming in the pool to celebrate Mother's Day. 'They boys, now young men, have made my Mother's Day EVERYTHING,' she wrote. Nobody 2 is in cinemas this Thursday.
News.com.au
3 hours ago
- News.com.au
Biocurious: In clinical terms, Singular Health ensures the right arm knows what the left arm is doing
Multiple patient imaging costs the US health system US$30 billion a year Singular's 3Dicom software provides a 'rail' to connect disparate image archives The company has launched a pilot program with the US hospitals intermediary, Provider Network Systems (PNS) For all the advances in medical imaging, clinicians face a simple everyday problem that in the US costs the health system US$30 billion a year. The issue? A patient is scanned at one facility but a doctor at another cannot access the image. As a result, the patient is sent off for a duplicate scan – which wastes more than money. 'This means unnecessary exposure to radiation and delays in diagnosis and treatment intervention and having to rebook consultations,' says Singular Health Group Ltd (ASX:SHG) chief operating officer Dr Martina Mariano. 'The whole process is highly inefficient.' Singular PACS a punch in giant US imaging market The nub of the problem is that the images reside in separate Picture Archive Communications Systems (PACS) within a hospital. In the US, parties such as ASX champion ProMedicus (ASX:PME) are entering contracts with large hospital groups that overhaul group-wide imaging systems at great cost. But for the time being the market remains highly fragmented and – as a result - the clinical right arm doesn't know what the left arm is doing. 'When it's not cost effective for them to replace the existing infrastructure … they need a bolt-on solution to transfer the data,' Mariano says. Developed over many years, Singular's 'PACS agnostic' 3Dicom software is a secure 'rail' that connect the facilities. 'We are a bolt-on solution,' Mariano says. 'We connect into those systems and enable the clinical provider outside of the network to receive those images.' Difficult cancer operation spurs a bright idea Perth-based Singular is making a concerted push into the US market, where it has entered a pivotal tie-up with Provider Network Systems (PNS), an expansive Managed Service Organisation (MSO). Given Singular's convoluted evolution, Mariano says there's been some investor confusion about the company's charter over the years. The company was founded in 2017 by Perth oncologist Dr Jason Tan, who had tackled a difficult inoperable ovarian cancer case. He developed the tech to convert the standard two-dimensional images in a Dicom format to interactive 3D models that could be used in virtual reality (VR) applications. Dicom is 'digital imaging and communications in medicine', a worldwide standard for medical images 'He could put the VR headset on and look at the anatomy of the patient to understand the relationship between the organ and the tumour mass,' Mariano says. 'That was very hard to see from standard 2D images." Needless to say, the operation succeeded. A new Singular focus Singular's business has evolved since then. The company itself was founded in 2018 as MedVR by Denning Chong, a Perth-based lawyer and venture capitalist, and the current CEO. Having by then adopted its current moniker, Singular listed on the ASX in February 2021, having raised $6 million at 20 cents apiece, After considerably more capex, the VR tool evolved to the 3Dicom viewing software. 'Rather than just working on VR, this conversion meant the software could operate on any consumer-grade device,' Mariano says. 'The company then added further functions, including the ability to share medical imaging records in a full-secure way (including between providers and patients). 'We can share the Dicom files – the imaging data - but also the attached reports.' The software enables medical professionals to visualise standard CT, MRI and PET scans in 2D and 3D in real-time, with built-in collaboration features. 3Dicom also deploys AI models to streamline clinical workflows, thus preventing misdiagnosis, enabling preventative diagnosis and stratifying patients according to risk. MSOs the way to go in US market Singular is preparing for its US rollout of 3Dicom, which the US Food and Drug Administration approved in October 2022. But it's one thing to have a you-beaut device approved and another to achieve commercial sales at scale. Singular cites an addressable US market of US$19 billion, across 1.3 million physicians. Under the software-as-a-service model, the company licenses the product at US$800 per practitioner, per year. But signing them up one-by-one will never cut it. Singular's business-to-business approach involves selling through the MSOs, which act as an intermediary between the hospitals, the physicians and the health insurers who pay the bill. 'The MSOs and the insurers manage multiple hospitals and clinicians. So, you can capture a lot of users in the one go,' Mariano says. Pilot project takes off In mid-June Singular inked a 'binding enterprise agreement' with Provider Network Systems, worth an initial $2 million. Ultimately, PNS covers 3.7 million insured patients. In the initial pilot phase, PNS will deploy 1000 3Dicom licences at facilities in Puerto Rico, Florida and Texas. PNS buys the licences for US$800 apiece, with a further US$500,000 payable on 'satisfaction of AI model marketplace and image repository development and integration'. If PNS is happy after the six-month pilot, a national rollout will ensue. Mariano says PNS alone spent US$1.5 billion a year on duplicate images. 'Even reducing this by 5% would be an incredible opportunity,' she says. 'MSOs get a fixed budget from the health insurers, so the only way to they can make money is by improving operational efficiencies.' The pilot program will quantify the cost savings. Despite its importance, the PNS tie up is non-exclusive. Indeed, the company has also carried out small pilots with other parties. Singular has also fielded interest from universities and associated teaching hospitals. This is in view of deploying 3Dicom for commercial and academic use. Bolstering the balance sheet In conjunction with the PNS deal, Singular raised $8 million at 35 cents per share. Having taken an earlier $500,000 cornerstone stake, PNS subscribed for a further $150,000 in the raising. Singular reported June quarter receipts of $498,000, taking the year's tally to $639,000. These inflows pertained mainly to the PNS deal. After quarterly operating cash burn of $324,000, the company has cash of $13.7 million. 'This is enough to fund the pilot and the national rollout," Mariano says. Singular shares have gained threefold over the last 12 months, valuing the company at a tad under $100 million. US first, then the world Currently, even the fast-growing Pro Medicus accounts for about 10% of the US medical imaging market. 'There's space for multiple players and all of them can make money even with a smaller market share,' Mariano says. 'So, there will still be lots of lack of interoperability.' She says Pro Medicus is not a direct competitor and 'we would be open to direct conversations and potential collaborations'. Mariano says Singular has been fortunate to secure a partner to navigate the complex US healthcare landscape. 'Because we are small, we can adapt quickly and in a way the meets the requirements of our customers and end users.' She says US entrants need to be clear on how they will be paid. Generally, that's either by way of reimbursement or proving a quantifiable saving to a party such as an MSO. 'The market is moving fast so you need to be agile and able to adapt quickly.' While Singular's – er singular – focus is on addressing the needs of MSOs and health plans, Mariano says the lack of interoperability is a worldwide issue. 'Our ultimate goal is to roll out 3Dicom globally'.
Daily Telegraph
4 hours ago
- Daily Telegraph
Sydney Sweeney's real controversy is her terrible new movie
Don't miss out on the headlines from New Movies. Followed categories will be added to My News. REVIEW Who cares about a jeans ad? Sydney Sweeney's real controversy is the bell-bottom-of-the-barrel quality of her new movie, Americana. Newish, that is. The wannabe Western crime drama premiered at South by Southwest back in March 2023 and is only now skulking into some cinemas. It's a violently annoying and annoyingly violent ensemble piece speckled with 'look how wacky we are!' characters that are impossible to put up with; a copycat Coen Brothers yarn with the depth of a tortilla. The cast breakdown reads like a parody. Sydney Sweeney's latest movie to hit cinemas, 'Americana', is 'terrible'. Sweeney plays Penny Jo, a shy South Dakota waitress who dreams of becoming a country singer but has a stammer. We are supposed to accept that the constantly photographed Sweeney is a wallflower nobody pays any attention to. The actress' fake speech impediment, meanwhile, comes off both rehearsed and not nearly rehearsed enough. Penny Jo finally gets some human face time with a creepy loser. That's Lefty (Paul Walter Hauser), a breathy schlub who has proposed to four women this year alone. Despite his name, he's right-handed and tells everybody that. There's a little boy named Cal (Gavin Maddox Bergman), who insists he's the reincarnation of Sitting Bull, and shoots his mum's abusive boyfriend, Dillon (Eric Dane), with an arrow. Sweeney plays an aspiring country music singer. He links up with Native American Ghost Eye (Zahn McClarnon), the leader of a gun-totin' group that protects their tribal legacy with rifles. He says he took his moniker from the Forest Whitaker indie 'Ghost Dog.' And spitfire Mandy (Halsey) has escaped from her father's Warren Jeffs-type sex cult. And on and on. I was fed up with 'Americana' by minute 10, and the succeeding 100 did nothing to change my mind. Everybody in this quirk brigade is trying to get their hands on a rare Native American ghost shirt that's worth hundreds of thousands of dollars. Ghost Eye wants the garment for its historic significance. The rest are hungry for the cash. At one point, a group of pretentious rich snobs displays it in their living room. The points writer-director Tony Tost makes are painfully obvious. Based on her prominence on the poster, you'd think so-so Sweeney is the lead. But the roles are equal in size — and irritation — and if there is any focal point, it's Halsey's Mandy, who has a meatier arc. Though, spoiler alert, Penny Jo finds her voice at the end, our eyes remain desert dry. Sweeney attended the "Americana" special screening in early August. Picture:for Lionsgate Tost bets that eccentricities will distract from his meandering, repetitive story, which amounts to an object changing hands a few times. Under more assured direction, the shoddy script could have amounted to something mediocre at least. When the Coens or Quentin Tarantino amp up the weird in their dark depictions of a dusty America, they do so with unsettling style and an enticingly skewed vision of reality to match. Of course, they, unlike Tost, also write strong screenplays. His 'Americana' is lifelessly visualised. Eye candy? Eye toothpaste. Pair pat-on-the-back lofty themes with bland imagery and artificially kooky characters speaking hokey, unconvincing dialogue, and you get a great big bore. Americana ends on a bloody standoff, an emotional death and a heartfelt reunion. And it's all as engrossing and moving as a tumbleweed. This story originally appeared on New York Post and was reproduced with permission Originally published as Sydney Sweeney's real controversy is her terrible new movie
